1. Search Result
Search Result
Results for "

DSPE-PEG2000-YIGSR

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Peptides

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-172476

    Liposome Cancer
    DSPE-PEG2000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG2000-YIGSR can be used for drug delivery .
    DSPE-PEG2000-YIGSR
  • HY-P0132
    YIGSR
    1 Publications Verification

    Laminin Fragment 929-933

    NO Synthase Cancer
    YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research .
    YIGSR
  • HY-P4651

    TGF-β Receptor Others
    H-Tyr-Ile-Gly-Ser-Arg-NH2 is a hexapeptide that is an essential fragment of laminin responsible for efficient cell adhesion and receptor binding. H-Tyr-Ile-Gly-Ser-Arg-NH2 promotes various epithelial cell adhesion activities .
    H-Tyr-Ile-Gly-Ser-Arg-NH2
  • HY-P10392AF

    Wnt β-catenin Cancer
    fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
    fStAx-35R TFA
  • HY-P10896

    Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-169232

    PROTACs Cancer
    PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
    PCC16 chloride
  • HY-P0132A

    NO Synthase Cancer
    YIGSR-Lys(N3) is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells. YIGSR blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, and inhibits shear-induced increase in eNOS expression of laminin cells . YIGSR-Lys(N3) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    YIGSR-Lys(N3)
  • HY-P11625

    RXFP Receptor Cardiovascular Disease
    R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
    R9-13
  • HY-P11830

    Amylin Receptor Metabolic Disease
    UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
    UDA-6
  • HY-P11596

    Integrin Cancer
    NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
    NOTA-Asp2-αvβ6L
  • HY-P3252AS

    Isotope-Labeled Compounds Complement System Inflammation/Immunology
    Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
    Pegcetacoplan-13C3,15N TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: